# Study Guide: Systemic Therapy for Melanoma (ASCO Guideline Update) This study guide is designed to synthesize the updated clinical practice guidelines from the American Society of Clinical Oncology (ASCO) regarding systemic therapy for cutaneous and noncutaneous melanoma. It focuses on neoadjuvant, adjuvant, and metastatic treatment settings based on recent randomized clinical trials (RCTs). --- ## Key Concepts and Recommendations ### 1. Staging and Population * **Staging Standard:** All recommendations refer to the **AJCC 8th Edition** criteria. * **Target Population:** Adult patients with cutaneous or noncutaneous (uveal, mucosal) melanoma. * **Primary Biomarker:** BRAF mutation status (specifically V600E/K) is the critical determinant for several treatment pathways. ### 2. Neoadjuvant Therapy (Pre-Surgical) * **Recommendation:** Neoadjuvant **pembrolizumab** (up to 3 courses) followed by surgery and then adjuvant pembrolizumab (up to 15 courses) is recommended for resectable **Stage IIIB to IV** cutaneous melanoma. * **Evidence:** Based on the SWOG S1801 trial, which showed a 23% improvement in 2-year event-free survival (EFS) compared to adjuvant-only pembrolizumab. ### 3. Adjuvant Therapy (Post-Surgical) * **Stage IIB/IIC:** Adjuvant **pembrolizumab** or **nivolumab** is now recommended. (Note: Adjuvant therapy is **not** recommended for Stage IIA outside of clinical trials). * **Stage IIIA-D (BRAF Wild-Type):** Nivolumab or pembrolizumab for 52 weeks. * **Stage IIIA-D (BRAF Mutant V600E/K):** Nivolumab, pembrolizumab, or the combination of **dabrafenib plus trametinib** for 52 weeks. * **Stage IV (Resected):** Adjuvant therapy should be offered. Options include nivolumab, pembrolizumab, nivolumab plus ipilimumab, or dabrafenib plus trametinib (for BRAF mutants). ### 4. Unresectable or Metastatic Cutaneous Melanoma * **First-Line Options:** * **Immunotherapy:** Nivolumab + ipilimumab, nivolumab + relatlimab, or single-agent anti-PD-1 (nivolumab or pembrolizumab). * **Targeted Therapy (BRAF Mutant only):** BRAF/MEK inhibitor combinations (Dabrafenib/Trametinib, Encorafenib/Binimetinib, or Vemurafenib/Cobimetinib). * **Preferences:** For BRAF-mutated disease, **nivolumab plus ipilimumab** is preferred as first-line therapy over BRAF/MEK inhibitor combinations based on the DREAMseq trial. ### 5. Noncutaneous Melanoma * **Uveal Melanoma:** **Tebentafusp** is recommended for HLA-A*02:01-positive patients with metastatic disease. * **Mucosal Melanoma:** Generally treated following the same recommendations as cutaneous melanoma (3.1 through 3.5). --- ## Summary of Recommended Dosing and Schedules | Setting | Regimen | Schedule Detail | | :--- | :--- | :--- | | **Neoadjuvant** | Pembrolizumab | 200 mg IV every 3 weeks (Max 3 courses pre-op; 15 courses post-op) | | **Adjuvant** | Nivolumab | 240 mg IV every 2 weeks or 480 mg every 4 weeks (52 weeks) | | **Adjuvant** | Dabrafenib + Trametinib | Dabrafenib 150 mg BID + Trametinib 2 mg QD (52 weeks) | | **Metastatic** | Nivolumab + Relatlimab | Relatlimab 160 mg and Nivolumab 480 mg IV every 4 weeks | | **Uveal** | Tebentafusp | 20 μg Day 1, 30 μg Day 8, then 68 μg weekly | --- ## Short-Answer Practice Questions 1. **Question:** Which specific drug and schedule is newly recommended for the neoadjuvant treatment of resectable stage IIIB-IV cutaneous melanoma? * **Answer:** Pembrolizumab, 200 mg IV once every 3 weeks for a maximum of three courses before surgery, followed by a maximum of 15 courses after surgery. 2. **Question:** Why does the Expert Panel now recommend adjuvant therapy for Stage IIB and IIC melanoma, but not Stage IIA? * **Answer:** Data from the KEYNOTE-716 and CheckMate 76K trials demonstrated significant recurrence-free survival (RFS) and event-free survival (EFS) benefits for Stage IIB/C. No such positive trial data exists for Stage IIA, leading the panel to recommend against it outside of clinical trials. 3. **Question:** In the context of resected Stage IIIA disease, what microscopic detail might lead a clinician to individualize therapy rather than strictly following the standard adjuvant protocol? * **Answer:** If the microscopic sentinel nodal metastasis is <1 mm in diameter. These patients have a better prognosis and lower risk of relapse, necessitating a careful risk-benefit discussion. 4. **Question:** According to the DREAMseq trial, what is the preferred treatment sequence for a patient with BRAF-mutated metastatic melanoma? * **Answer:** Starting with nivolumab plus ipilimumab (immunotherapy) is preferred over starting with BRAF/MEK inhibitor combination therapy. 5. **Question:** Talimogene laherparepvec (T-VEC) is no longer recommended for which specific patient group? * **Answer:** Patients with BRAF wild-type disease who have progressed on anti-PD-1 therapy. 6. **Question:** What is the prerequisite for prescribing Tebentafusp to a patient with metastatic uveal melanoma? * **Answer:** The patient must be HLA-A*02:01-positive. --- ## Essay Prompts for Deeper Exploration 1. **The Shift to Neoadjuvant Care:** Discuss the clinical rationale and evidence provided by the SWOG S1801 trial for moving systemic therapy to the neoadjuvant setting for resectable melanoma. What are the potential biological and logistical advantages of this approach? 2. **The Complexity of BRAF Mutant Management:** Compare and contrast the use of immunotherapy versus BRAF/MEK inhibitors in both the adjuvant and metastatic settings. Analyze the factors (toxicity, survival data, and sequence) that influence the Expert Panel’s preference for immunotherapy in first-line metastatic care. 3. **Challenges in Noncutaneous Melanoma Research:** Using uveal and mucosal melanoma as examples, explain why developing evidence-based guidelines is more difficult for noncutaneous types. Discuss how the Expert Panel uses "informal consensus" and "evidence extrapolation" when high-quality RCT data is absent. 4. **Shared Decision-Making and Toxicity:** The guidelines emphasize the importance of "shared decision-making." Discuss the specific toxicities associated with combination therapies (like nivolumab + ipilimumab) versus single agents, and how these factors should be communicated to patients to determine the optimal treatment course. --- ## Glossary of Key Terms * **Adjuvant Therapy:** Systemic treatment administered after the primary treatment (usually surgery) to lower the risk of the cancer returning. * **Anti-PD-1 (Programmed Cell Death Protein 1):** A type of checkpoint inhibitor (e.g., Nivolumab, Pembrolizumab) that helps the immune system recognize and attack cancer cells. * **BRAF Mutation:** A mutation in the BRAF gene (most commonly V600E or V600K) that drives cell growth in about half of all cutaneous melanomas. * **Checkpoint Inhibitor:** A type of immunotherapy that blocks proteins that keep the immune system from attacking cancer cells. Examples include anti-PD-1, anti-CTLA-4 (Ipilimumab), and anti-LAG-3 (Relatlimab). * **Event-Free Survival (EFS):** The length of time after primary treatment ends that the patient remains free of certain complications or events (like recurrence or progression). * **HLA-A*02:01:** A specific human leukocyte antigen type used as a biomarker to determine eligibility for tebentafusp in uveal melanoma. * **MEK Inhibitor:** A drug that blocks MEK proteins, used in combination with BRAF inhibitors (e.g., Trametinib, Binimetinib, Cobimetinib) to treat BRAF-mutant melanoma. * **Neoadjuvant Therapy:** Treatment given as a first step to shrink a tumor before the main treatment (usually surgery) is performed. * **Recurrence-Free Survival (RFS):** The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer. * **Systemic Therapy:** Treatment that uses substances that travel through the bloodstream, reaching and affecting cells throughout the body (e.g., immunotherapy, targeted therapy, chemotherapy). * **T-VEC (Talimogene Laherparepvec):** An oncolytic gene therapy (a weakened herpes virus) injected directly into melanoma lesions.